ADILMEDIUM SIGNALFINANCIAL10-K

ADIL executed a 1-for-25 reverse stock split while significantly improving its cash position and reducing net losses by 40%.

The reverse stock split typically signals management's attempt to boost share price for compliance or investor perception reasons, though the underlying share count reduction from ~6.6M to ~1.4M shares represents substantial dilution that occurred prior to the split. The improved financial metrics suggest better operational efficiency or successful fundraising, but biotech companies often use reverse splits when facing delisting threats or low share prices.

Comparing 2026-03-05 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

ADIL showed marked improvement across key financial metrics, with cash increasing 57% to $5.9M and net losses decreasing 40% to $8.0M, while R&D expenses declined 19% to $2.6M. Total assets grew 32% and stockholders' equity increased 30%, suggesting either successful fundraising or better cost management. However, current liabilities increased 43%, and the substantial improvement in per-share metrics must be viewed alongside the 1-for-25 reverse stock split that masks the true dilution impact on existing shareholders.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+56.8%
$3.8M$5.9M

Cash position surged 56.8% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+52.3%
$4.1M$6.2M

Current assets grew 52.3% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
+43.1%
$976K$1.4M

Liabilities grew 43.1% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+43.1%
$976K$1.4M

Current liabilities surged 43.1% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
+39.6%
-$13.2M-$8.0M

Net income grew 39.6% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+32.3%
$5.0M$6.7M

Asset base grew 32.3% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+29.7%
$4.1M$5.3M

Equity base grew 29.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
-18.9%
$3.2M$2.6M

R&D spending cut 18.9% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-04
ADDED
As of March 4, 2026, the issuer had 1,427,970 shares of common stock outstanding.
On February 5, 2026, we effected a one-for-twenty-five reverse stock split (the Reverse Stock Split ) of our authorized, issued and outstanding common stock.
Unless otherwise noted, all references to share amounts in this Annual Report reflect the Reverse Stock Split.
ii NOTE REGARDING COMPANY REFERENCES Throughout this Annual Report on Form 10-K, Adial, the Company, we, us and our refer to Adial Pharmaceuticals, Inc.
Risks Relating to Our Company We have incurred losses since our inception and anticipate that we will continue to incur losses in the future.
+7 more — sign up free →
REMOVED
As of February 28, 2025, the issuer had 6,574,588 shares of common stock outstanding.
Risks Relating to Our Company We have a limited operating history and have incurred significant losses since our inception.
We will need to secure additional financing, which may not be available to us on favorable terms, if at all.
For ondansetron, under short-term use, there are currently no long-term use clinical safety data available.
The FDA and/or EMA may not accept our planned Phase 3 endpoints for final approval of AD04.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →